Development of a Protein Nanoparticle Platform for Targeting EGFR Expressing Cancer Cells

Jakob W, et al., 90(7):1230-36, Chemical Technology and Biotechnology, 2014

This investigation provides evidence that the antibody fragments targeting the epidermal growth factor receptor (EGFR), once tethered to E2 nanoparticles are still capable of targeting/recognizing EGFR overexpressing cancer cells. There are previous reports where protein-based nanoparticles that are being developed for cancer drug delivery and diagnostics. Particularly, the E2 protein derived from pyruvate dehydrogenase complex in B. subtilis assembles into a 60-subunit protein cage-structure that is capable of encapsulating cancer therapeutics. In this particular study, they conjugated variants of the anti-EGFR antibody fragment with E2 protein (containing specific cysteine residues) via a maleimide-specific crosslinker. The binding between conjugated E2 particle and recombinant EGFR was monitored using a BLItz instrument. The recombinant EGFR-Fc and the recombinant VEGFR-Fc (negative control) proteins immobilized on to Protein A biosensors helped in determining the binding interactions. The wild-type EGFR (from cancer cells) binding to E2 particles was confirmed by a Flow cytometry assay

Read More

We use cookies to personalize content and improve your browsing experience.

We also use analytics & advertising services. To opt-out click for more information.